Electroacupuncture-induced pressor and chronotropic effects in anesthetized rats. 2006

Jiuan-Miaw Liao, and Hua Ting, and Shin-Da Lee, and Chao-Hsun Yang, and Ying-Ming Liou, and Mei-Lin Peng, and Shih-Jei Tsai, and Chih-Feng Lin, and Tzer-Bin Lin
Department of Physiology, College of Medicine Chung-Shan Medical University, No. 110, Chang-Kuo North Rd Section 1, Taichung, Taiwan 10018.

The effects of electroacupuncture (Ea) on circulatory dynamics were investigated in anesthetized rats. The arterial blood pressure (BP) and the heart rate (HR) in response to Ea stimulations at the Tsusanli point (St-36) and the Hoku point (Li-4) were tested by a low frequency Ea (2 Hz; LFEa) and a high frequency Ea (20 Hz; HFEa) with stimulation intensities 20 times the motor threshold. Neither the HR nor the BP was affected when the Tsusanli point was stimulated. Whereas, Ea stimulations at the Hoku point elicit chronotropic and pressor effects. The patterns of pressor responses caused by the LFEa were different from that of an HFEa, i.e., the LFEa elicited a tonic effect, while an HFEa had a phasic one. The HFEa-induced pressor and chronotropic effects were attenuated, while the LFEa induced effects were completely blocked by an intravenous infusion of an alpha-adrenergic blocker (moxisylyte 0.2 mg/min/kg, i.v., for 20 min). A co-infusion with alpha-and beta-adrenergic blockers (propanolol 0.2 mg/min/kg, i.v., for 20 min) completely blocked the HFEa-induced pressor and chronotropic effects. We concluded that Ea stimulations, at the Hoku acupoint, with appropriate stimulation parameters can increase and maintain BP. Furthermore, the LFEa stimulation activates sympathetic vasomotor tone, whereas the HFEa stimulation causes an additional potentiation on the sympathetic drive to the heart.

UI MeSH Term Description Entries
D011433 Propranolol A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs. Dexpropranolol,AY-20694,Anaprilin,Anapriline,Avlocardyl,Betadren,Dociton,Inderal,Obsidan,Obzidan,Propanolol,Propranolol Hydrochloride,Rexigen,AY 20694,AY20694,Hydrochloride, Propranolol
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D005260 Female Females
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse
D000317 Adrenergic alpha-Antagonists Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. Adrenergic alpha-Receptor Blockaders,alpha-Adrenergic Blocking Agents,alpha-Adrenergic Receptor Blockaders,alpha-Blockers, Adrenergic,Adrenergic alpha-Blockers,alpha-Adrenergic Antagonists,alpha-Adrenergic Blockers,Adrenergic alpha Antagonists,Adrenergic alpha Blockers,Adrenergic alpha Receptor Blockaders,Agents, alpha-Adrenergic Blocking,Antagonists, alpha-Adrenergic,Blockaders, Adrenergic alpha-Receptor,Blockaders, alpha-Adrenergic Receptor,Blockers, alpha-Adrenergic,Blocking Agents, alpha-Adrenergic,Receptor Blockaders, alpha-Adrenergic,alpha Adrenergic Antagonists,alpha Adrenergic Blockers,alpha Adrenergic Blocking Agents,alpha Adrenergic Receptor Blockaders,alpha Blockers, Adrenergic,alpha-Antagonists, Adrenergic,alpha-Receptor Blockaders, Adrenergic
D000319 Adrenergic beta-Antagonists Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. Adrenergic beta-Antagonist,Adrenergic beta-Receptor Blockader,Adrenergic beta-Receptor Blockaders,beta-Adrenergic Antagonist,beta-Adrenergic Blocker,beta-Adrenergic Blocking Agent,beta-Adrenergic Blocking Agents,beta-Adrenergic Receptor Blockader,beta-Adrenergic Receptor Blockaders,beta-Adrenoceptor Antagonist,beta-Blockers, Adrenergic,beta-Adrenergic Antagonists,beta-Adrenergic Blockers,beta-Adrenoceptor Antagonists,Adrenergic beta Antagonist,Adrenergic beta Antagonists,Adrenergic beta Receptor Blockader,Adrenergic beta Receptor Blockaders,Adrenergic beta-Blockers,Agent, beta-Adrenergic Blocking,Agents, beta-Adrenergic Blocking,Antagonist, beta-Adrenergic,Antagonist, beta-Adrenoceptor,Antagonists, beta-Adrenergic,Antagonists, beta-Adrenoceptor,Blockader, Adrenergic beta-Receptor,Blockader, beta-Adrenergic Receptor,Blockaders, Adrenergic beta-Receptor,Blockaders, beta-Adrenergic Receptor,Blocker, beta-Adrenergic,Blockers, beta-Adrenergic,Blocking Agent, beta-Adrenergic,Blocking Agents, beta-Adrenergic,Receptor Blockader, beta-Adrenergic,Receptor Blockaders, beta-Adrenergic,beta Adrenergic Antagonist,beta Adrenergic Antagonists,beta Adrenergic Blocker,beta Adrenergic Blockers,beta Adrenergic Blocking Agent,beta Adrenergic Blocking Agents,beta Adrenergic Receptor Blockader,beta Adrenergic Receptor Blockaders,beta Adrenoceptor Antagonist,beta Adrenoceptor Antagonists,beta Blockers, Adrenergic,beta-Antagonist, Adrenergic,beta-Antagonists, Adrenergic,beta-Receptor Blockader, Adrenergic,beta-Receptor Blockaders, Adrenergic
D000758 Anesthesia A state characterized by loss of feeling or sensation. This depression of nerve function is usually the result of pharmacologic action and is induced to allow performance of surgery or other painful procedures.
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013948 Moxisylyte An alpha-adrenergic blocking agent that is used in Raynaud's disease. It is also used locally in the eye to reverse the mydriasis caused by phenylephrine and other sympathomimetic agents. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1312) Thymoxamine,Thymoxyalcylamine,Acetoxythymoxamine,Carlytène,Icavex,Moxisylyte Hydrochloride,Hydrochloride, Moxisylyte
D015669 Acupuncture Points Designated locations along nerves or organ meridians for inserting acupuncture needles. Acupoints,Acupoint,Acupuncture Point,Point, Acupuncture,Points, Acupuncture

Related Publications

Jiuan-Miaw Liao, and Hua Ting, and Shin-Da Lee, and Chao-Hsun Yang, and Ying-Ming Liou, and Mei-Lin Peng, and Shih-Jei Tsai, and Chih-Feng Lin, and Tzer-Bin Lin
January 2004, Neuropeptides,
Jiuan-Miaw Liao, and Hua Ting, and Shin-Da Lee, and Chao-Hsun Yang, and Ying-Ming Liou, and Mei-Lin Peng, and Shih-Jei Tsai, and Chih-Feng Lin, and Tzer-Bin Lin
January 2000, Journal of hepatology,
Jiuan-Miaw Liao, and Hua Ting, and Shin-Da Lee, and Chao-Hsun Yang, and Ying-Ming Liou, and Mei-Lin Peng, and Shih-Jei Tsai, and Chih-Feng Lin, and Tzer-Bin Lin
June 2003, American journal of physiology. Heart and circulatory physiology,
Jiuan-Miaw Liao, and Hua Ting, and Shin-Da Lee, and Chao-Hsun Yang, and Ying-Ming Liou, and Mei-Lin Peng, and Shih-Jei Tsai, and Chih-Feng Lin, and Tzer-Bin Lin
December 2009, The Chinese journal of physiology,
Jiuan-Miaw Liao, and Hua Ting, and Shin-Da Lee, and Chao-Hsun Yang, and Ying-Ming Liou, and Mei-Lin Peng, and Shih-Jei Tsai, and Chih-Feng Lin, and Tzer-Bin Lin
December 1965, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
Jiuan-Miaw Liao, and Hua Ting, and Shin-Da Lee, and Chao-Hsun Yang, and Ying-Ming Liou, and Mei-Lin Peng, and Shih-Jei Tsai, and Chih-Feng Lin, and Tzer-Bin Lin
June 1987, Neuroscience letters,
Jiuan-Miaw Liao, and Hua Ting, and Shin-Da Lee, and Chao-Hsun Yang, and Ying-Ming Liou, and Mei-Lin Peng, and Shih-Jei Tsai, and Chih-Feng Lin, and Tzer-Bin Lin
June 1968, European journal of pharmacology,
Jiuan-Miaw Liao, and Hua Ting, and Shin-Da Lee, and Chao-Hsun Yang, and Ying-Ming Liou, and Mei-Lin Peng, and Shih-Jei Tsai, and Chih-Feng Lin, and Tzer-Bin Lin
December 1975, Arquivos brasileiros de cardiologia,
Jiuan-Miaw Liao, and Hua Ting, and Shin-Da Lee, and Chao-Hsun Yang, and Ying-Ming Liou, and Mei-Lin Peng, and Shih-Jei Tsai, and Chih-Feng Lin, and Tzer-Bin Lin
January 2011, Acta cirurgica brasileira,
Jiuan-Miaw Liao, and Hua Ting, and Shin-Da Lee, and Chao-Hsun Yang, and Ying-Ming Liou, and Mei-Lin Peng, and Shih-Jei Tsai, and Chih-Feng Lin, and Tzer-Bin Lin
June 2001, Japanese journal of pharmacology,
Copied contents to your clipboard!